# Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment

> **NCT00288522** · PHASE2 · TERMINATED · sponsor: **Ipsen** · enrollment: 5 (actual)

## Conditions studied

- Thyroid-Associated Ophthalmopathy

## Interventions

- **DRUG:** Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days

## Key facts

- **NCT ID:** NCT00288522
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-01
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2020-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00288522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00288522, "Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00288522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*